Canaccord Genuity Group reiterated their buy rating on shares of TriSalus Life Sciences (NASDAQ:TLSI - Free Report) in a report issued on Friday,Benzinga reports. They currently have a $11.00 price target on the stock.
Other equities research analysts have also issued research reports about the stock. Roth Mkm reissued a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Lake Street Capital assumed coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a "buy" rating and a $10.00 price target on the stock. Finally, Cantor Fitzgerald started coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an "overweight" rating and a $10.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, TriSalus Life Sciences currently has a consensus rating of "Buy" and a consensus price target of $11.56.
Check Out Our Latest Research Report on TriSalus Life Sciences
TriSalus Life Sciences Trading Up 0.5 %
TriSalus Life Sciences stock traded up $0.03 during trading hours on Friday, hitting $5.55. 20,110 shares of the stock traded hands, compared to its average volume of 42,960. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The firm's 50-day moving average price is $5.42 and its two-hundred day moving average price is $4.74. The company has a market cap of $169.24 million, a PE ratio of -2.22 and a beta of 0.48.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.12 million. On average, sell-side analysts expect that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.
Insider Transactions at TriSalus Life Sciences
In related news, insider Sean Murphy purchased 15,000 shares of the business's stock in a transaction on Monday, January 27th. The stock was acquired at an average price of $5.31 per share, with a total value of $79,650.00. Following the completion of the acquisition, the insider now owns 182,732 shares of the company's stock, valued at approximately $970,306.92. This trade represents a 8.94 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO James Emmett Young acquired 6,000 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was bought at an average cost of $5.65 per share, for a total transaction of $33,900.00. Following the purchase, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at approximately $169,500. This trade represents a 25.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 54,856 shares of company stock worth $294,608 in the last ninety days. Insiders own 32.80% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in TLSI. Walleye Capital LLC purchased a new position in TriSalus Life Sciences during the third quarter valued at approximately $66,000. Renaissance Technologies LLC bought a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at $67,000. Virtu Financial LLC bought a new position in TriSalus Life Sciences in the 3rd quarter worth $92,000. Vestcor Inc purchased a new stake in TriSalus Life Sciences in the 3rd quarter worth $108,000. Finally, Connective Capital Management LLC purchased a new stake in TriSalus Life Sciences in the 4th quarter worth $140,000. 2.58% of the stock is currently owned by institutional investors.
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Stories
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
